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Abstract: A relatively large body of evidence supports the notion that glomerular capillary 
wall and mesangial alterations in diabetic nephropathy involve biochemical alterations of 
glycoproteins in these structures. Evidence in experimental animals rendered diabetic reveals 
that the administration of heparin and other anionic glycoproteins can effectively prevent the 
biochemical alterations that promote albuminuria. Moreover, angiotensin II inhibits heparan 
sulfate synthesis, while heparins modulate angiotensin II signaling in glomerular cells, inhibit-
ing aldosterone synthesis and lowering proteinuria in diabetes patients. Sulodexide, a mixture 
of heparin and dermatan sulfate, appears to be a promising treatment for diabetic proteinuria 
partially resistant to renin–angiotensin system blocking agents. Sulodexide prevents heparan 
sulfate degradation, thus allowing reconstruction of heparan sulfate content and restoration 
of glomerular basement membrane ionic permselectivity. The antiproteinuric effect appears 
to be mainly related to the basal proteinuria and consequently to the duration of treatment 
in a relatively large number of small clinical trials. On the other hand, several sulodexide 
pharmacodynamic properties could improve the prognosis of chronic kidney disease patients, 
also independently from its antiproteinuric effect. However, sulodexide development as an 
antiproteinuric drug needs to be continued, in order to define which kind of patients could 
better respond to this treatment.
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Introduction
Diabetes mellitus is strongly associated with cardiovascular disease morbidity and 
mortality, accelerating the vascular aging process and in particular the pathogenesis 
of atherosclerosis. Diabetic nephropathy is a highly important cause of morbidity and 
mortality in patients with type 1 and type 2 diabetes mellitus, either directly and as 
a risk factor for cardiovascular disease.1 In particular, diabetic kidney disease occurs 
in 20% to 40% of patients with diabetes mellitus and is the leading cause of chronic 
kidney disease and end-stage renal disease.2
Recent evidence shows that an early multipharmacological approach is able to 
slow the progression of diabetic nephropathy to end stage renal disease (ESRD), the 
disease rarely stops and slightly regresses just in few selected and optimally treated 
patients.3 In this context, there is a strong need for new agents able to significantly 
modify the patient disease history.
The aim of this review is to evaluate the potential role of glycosaminoglycans (and 
in particular sulodexide) as antiproteinuric and kidney protective drugs.International Journal of Nephrology and Renovascular Disease 2010:3 100
Gaddi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
supports the key role of this glycocalyx and glycocalyx 
composition on glomerular function.10
Angiotensin II receptor blockers are renin–angiotensin 
system (RAS) modulators with known antiproteinuric 
  activity.11 Angiotensin II inhibits heparan sulfate synthesis, 
while heparins modulate angiotensin II signaling in 
  glomerular cells, inhibiting aldosterone synthesis and lower-
ing proteinuria in diabetes patients (but less in other forms of 
proteinuric renal diseases).12 In this context, heparinoids have 
been considered as potentially useful antiproteinuric drugs 
that could have synergistic effects with RAS modulator.13
Sulodexide as an antiproteinuric 
agent: the available evidence
Sulodexide is a highly purified mixture of GAGs composed 
of a fast-moving heparin fraction (80%) and dermatan sulfate 
(20%), with a low molecular weight, a high oral bioavail-
ability, and antithrombotic and profibrinolytic activity.14 
It also appears to be a promising treatment for diabetic 
proteinuria partially resistant to RAS blocking agents.15 
Sulodexide concentrates in renal parenchyma for a long 
time after administration.16 From preliminary trials it has 
been supposed that sulodexide reduces albuminuria acting 
in vivo as a heparinase inhibitor that reaches the glomerular 
capillary wall and prevents heparan sulfate degradation, 
thus allowing reconstruction of heparan sulfate content 
and restoration of glomerular basement membrane ionic 
permselectivity.17
Recent in vitro experiments on umbelical human veins 
demostrated that sulodexide supplementation restores the 
glycocalyx structure and barrier properties by increasing the 
trans-endothelial albumin leakage induced by hyperglycemic 
conditions.18
The antiproteinuric effect appears to be mainly related 
to the basal proteinuria and consequently to the duration of 
treatment.19 Moreover, at least a part of the renal histological 
degradation observed in diabetes is related to inflammatory 
processes. Sulodexide seems to have powerful antinflamma-
tory activity in experimental models.20 In a model of cultured 
human umbilical endothelial cells exposed to high glucose 
concentration, sulodexide suppresses cellular inflamma-
tion and prevents glucose cytotoxicity:21 sulodexide is able 
to reverse the glucose-related cell release of free oxygen 
radicals, monocyte chemotactic protein-1 (MCP-1) and 
interleukin-6 (IL-6), and the inactivation of cell-repairing 
mechanism enabling the exposition to glucose. Moreover, 
in rats with streptozocin-induced diabetes, sulodexide exerts 
direct endothelial protective effects.22
Glycosaminoglycans role  
in proteinuria management
Glycosaminoglycans (GAGs) are long unbranched muco-
polysaccharides consisting of a repeating disaccharide 
unit. Apart from hyaluronan, which is uniquely synthesized 
without a protein core and is “spun out” by enzymes at cell 
surfaces directly into the extracellular space, the other GAGs 
are usually added to protein cores in the Golgi apparatus to 
yield proteoglycans.4 It has been proposed that hemodynamic 
alterations and structural changes in glomerular basement 
membrane glycosaminoglycans may play a role in the 
pathogenesis of proteinuria. The glomerular filtration barrier 
consists of fenestrated glomerular endothelium, podocyte 
foot processes/slit diaphragms, and intervening glomerular 
basement membrane. Its characterization as both a size- and 
charge-selective barrier emerged from studies conducted 
decades ago. The charge selectivity phenomenon is receiving 
renewed attention now that the identities and mechanisms 
of synthesis of relevant molecules are known.5 Attention 
has focused on glomerular basement membrane heparan 
sulfate proteoglycans, long considered primary charge bar-
rier components, even if recent in vivo manipulations of 
glomerular heparan sulfate proteoglycans redefined (but not 
excluded) their role or their anionic charge in glomerular 
filtration.6 In fact an experimental model of non-diabetic 
mice, knock-out for the Ext1 gene encoding a subunit of 
heparan sulfate co-polymerase, develops a proteinuria that 
is less impressive than that expected from the available 
knowledge on renal physiology.7 However, a relatively large 
body of evidence supports the notion that glomerular capil-
lary wall and mesangial alterations in diabetic nephropathy 
involve pathobiochemical alterations of glycoproteins 
in these structures. Evidence in experimental animals 
  rendered diabetic reveals that the administration of heparin 
and other anionic glycoproteins can effectively prevent the 
  biochemical alterations that promote albuminuria.8 More-
over, in renal biopsies of different human primary protein-
uric diseases, pronounced tubulointerstitial heparan sulfate 
proteoglycans alteration are evident and strongly related to 
the inflammatory processes.9
Moreover, GAGs strongly influence thickness, integrity 
and permselectivity of the endothelial glycocalyx, a luminal 
layer composed of several proteoglycans and a special class 
of heavily glycosylated glycoproteins. Glycocalyx composi-
tion is strongly alterated in diabetes patients, who typically 
show early sign of renal damage. The recent demonstration 
that angiopoietin-1 also modifies basal kidney-microvessel 
permeselectivity acting on the glomerular glycocalyx further International Journal of Nephrology and Renovascular Disease 2010:3 101
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A large number of studies, mainly carried out in type 1 
and 2 diabetes patients, have strongly suggested the potential 
role of sulodexide as an antiproteinuric agent (Table 1). The 
majority of these studies, however, were small, had an open 
design, were of short duration, and involved inhomogeneous 
patient categories. However, at least 15 out of 16 studies, 
involving 594 patients, reported a significant antiproteinuric 
effect of sulodexide.
It remains to be clarified if sulodexide could exert an 
additive antiproteinuric effect in patients treated with fully 
dosed angiotensin-converting enzyme inhibitor (ACEI) or 
an angiotensin receptor blocker (ARB).
In a pilot study, return to normoalbuminuria or a decrease 
in albumine:creatinine ratio (ACR) of at least 50% from the 
baseline value was achieved in 25.3% of patients with persis-
tent albuminuria in spite of being treated with the maximum 
recommended dose of an ACEI or an ARB.23 Interestingly, 
a very favorable trend for an increased rate of therapeutic suc-
cess was obtained in the sulodexide group receiving the daily 
dose of 200 mg (33.3% versus 15.4% of patients receiving 
Table 1 Clinical trials testing antiproteinuric effects of sulodexide in diabetes patients
Number of  
patients
Type of  
patients
Dose  Duration of  
treatment
Main results  References 
18 Type 2 diabetes 600 lipoproteinlipase- 
releasing units/day Iv
3 weeks Albuminuria fall in 89% of patients,  
proteinuria normalization in the  
9 microalbuminuric patients
Shestakova19
15 Type 1 diabetes 600 lipoproteinlipase- 
releasing units/day Iv
3 weeks Albuminuria fall after the first week,  
maintained also 6 weeks after  
treatment cessation
Szela-
chowska46
15 Type 2 diabetes 600 lipoproteinlipase- 
releasing units/day IM
4 weeks Albuminuria fall in the 60% of  
patients, reversed after
Sorrenti47
20 Type 2 diabetes 100 mg/day 4 months Significant reduction in albumin  
excretion rate, fibrinogen and  
blood pressure
Solini48
53 Type 2 and type 1  
diabetes
600 lipoproteinlipase- 
releasing units/day IM
3 weeks Significant reduction of  
albuminuria in 72% of patients,  
slower in type 2 diabetics
Skrha49
36 Type 1 diabetes 600 lipoproteinlipase- 
releasing units/day IM  
5 days/week
3 weeks Significant reduction of  
albuminuria in 90% of patients,  
slower in macroalbuminuric patients
Dedov50
14 Type 1 diabetes 60 mg vial of sulodexide/ 
day for 10 days, and then  
orally with 25 mg capsules  
twice a day for 21 days
31 days Significant reduction of  
albuminuria with normalization in  
40% of microalbuminurics  
and 25% of macroalbuminurics
Poplawska51
35 Type 2 and type 1 
 diabetes
600 lipoproteinlipase- 
releasing units/day IM  
5 days/week
15 days Significant reduction of  
albuminuria in 70% of patients,  
persistent 3 weeks after  
treatment cessation
Perusicová52
20 Type 2 and type 1 
diabetes
600 lipoproteinlipase- 
releasing units/day  
IM 5 days/week
3 weeks Quickly reversible  
albuminuria in all patients
Zalevskaia53
20 Type 1 diabetes 600 lipoproteinlipase- 
releasing units/day IM  
5 days/week
3 weeks Significant reduction of  
albuminuria in 70% of patients, and  
persisted in 60% 6 weeks after  
drug discontinuation
Rasovskiı ˘54
20 Type 2 and type 1  
diabetes
600 lipoproteinlipase- 
releasing units/day IM  
5 days/week
3 weeks Significant reduction in albuminuria  
and serum NAG activity
Skrha55
20 Type 2 and type 1  
diabetes
60 mg/d IM  
100 mg/d PO
3 weeks  
8 weeks
Albumin excretion rate reduced  
after both treatment phases in  
macroalbuminuric, but not  
microalbuminuric patients
Oksa56
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placebo; P = 0.075), which was the more effective dose also 
in the largest published study.24 In particular, this trial clearly 
showed for the first time that sulodexide, 200 mg/day for 
4 months, was able to significantly decrease albuminuria 
(both versus placebo and baseline) independently of the con-
comitant administration of ACEI, but at an unspecified daily 
dosage. The decrease in the albumin excretion rate at the end 
of treatment was 40% and 46% versus baseline in patients 
receiving or not receiving ACEI, respectively (P  0.05).
To the best of our knowledge only one trial has tested 
the effect of endovenous sulodexide administration on renal 
disease other than that caused by diabetes.25 In this trial 
the researchers enrolled patients with bioptic diagnosis of 
different glomerulonephritis, and observed after 1 month 
of treatment that overall 85% of patients experienced a 
significant reduction in proteinuria, which was significantly 
more impressive in patients with mesangiocapillary than 
in those with membrano- and mesangioproliferative glo-
merulonephritis. Moreover, the decline of proteinuria was 
more relevant in GAG(+) patients with important proximal 
tubular necrosis and moderate to severe myofibroblast 
infiltrates than in GAG(–) patients with mild interstitial 
involvement.26
On the basis of the above-cited preclinical and clinical 
evidence, the use of sulodexide has also been suggested by 
experts for the treatment of serious chronic kidney diseases 
(CKD) other than those caused by diabetes. The most interest-
ing is probably the management of the membranoprolifera-
tive glomerulonephritis type II (or dense deposit disease), 
a rare and serious renal genetic disease which affect 2 to 3 
people per million and leads to renal failure within 10 years in 
50% of affected children, with a worse prognosis after kidney 
transplantation than other genetic glomerulonephritis.27
However new trials have to be carried out to confirm 
these preliminary results and hypotheses.
Other sulodexide pharmacological 
effects potentially useful in the 
diabetic CKD patient
It is well known that diabetes patients are more likely to 
develop vein insufficiency and their related sequelae. The 
antithrombotic effects of sulodexide in patients affected 
by deep vein thrombosis28,29 and venous leg ulcers30,31 have 
been adequately investigated in different clinical trials. 
However, there is some evidence that sulodexide could also 
reduce the arterial disease risk, which is usually very high 
in diabetes patients with CKD,32 through a large number of 
  pharmacological actions (Table 2).
Table 1 (Continued)
Number of  
patients
Type of  
patients
Dose  Duration of  
treatment
Main results  References 
223 Type 2 and type 1  
diabetes
50 mg/d, 100 mg/d,  
or 200 mg/d PO
4 months Dose-dependent reduction in albumin 
excretion rate
Gambaro24
60 Type 2 and type 1  
diabetes
50 mg/d PO 12 months Albuminuria strongly reduced in all  
patients vs controls and vs baseline
Achour57
45 Type 1 diabetes 120 mg/d PO 6 months Reduction in albuminuria and  
NAG excretion, increase in renal  
vascular function
Sulikowska58
149 
 
 
 
 
 
Obese type 2  
diabetics with  
proteinuria resistant 
to therapy with 
ACeI or ARBs 
 
200–400 mg/d PO in  
addition to ACeI or ARBs 
 
 
 
 
6 months 
 
 
 
 
 
25.3% and 33.3% of the patients  
respectively in the two sulodexide  
groups combined and in the 200 mg/d  
group achieved a significant reduction or  
normalization of albuminuria vs 15.4%  
of the patients in the control group  
(P = 0.26 and P = 0.07, respectively)
Heerspink23 
 
 
 
 
 
Abbreviations: ACeI, angiotensin-converting enzyme inhibitor; ARB, angiotension-receptor blocker; IM, intramuscular; Iv, intravenous; PO, by mouth; NAG,   
N-acetyl-beta-glucosaminidase.
Table 2 Potential cardiovascular beneficial effects of sulodexide 
and glycosaminoglycans
Antithrombotic action
Decrease of oxidative stress
Hypolipidemic actions
Prevention of glucose toxicity
Suppression of cellular inflammation
Antiproteinuric effects
Improvement of endothelial function and vascular elasticity
Interactions with AT-II signaling and RAS systemInternational Journal of Nephrology and Renovascular Disease 2010:3 103
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Two different meta-analyses of the available clinical trials 
have show that sulodexide treatment improves the pain-free 
walking distance in patients affected by peripheral occlusive 
artery disease.33,34 This effect could be related to different 
sulodexide activities. First, the sulodexide-treated patients 
have higher peak flow and rest flow in the lower limbs.35 
Moreover, sulodexide treatment improves the patient’s 
lipid and hemorrheological profile.36 In particular, sulo-
dexide improves the typical lipid components of metabolic 
syndrome, which is a predictor of both CKD worsening 
and cardiovascular disease risk in CKD patients.37 Recent 
data also support a significant anti-inflammatory action of 
  sulodexide in the endothelial cells and a protective effect 
of the drug against glucose cytotoxicity. The experiments 
were performed on in vitro cultured human umbilical endo-
thelial cells kept for 7 days in standard medium or in the 
same medium but supplemented with glucose. Sulodexide 
inhibited the intracellular generation of free radicals in a 
dose-dependent manner (by up to 32%), as well as monocyte 
chemotactic protein-1 (MCP-1) (by up to 60%) and IL-6 (by 
up to 69%). Cells cultured in a medium with glucose gener-
ated more free radicals (+20%) and released more MCP-1 
(+113%) and IL-6 (+26%). Cell monolayers treated with 
glucose had a decreased ability to heal after mechanical injury 
(–28%). All these glucose effects were reversed when cells 
were exposed to sulodexide simultaneously.19
In the long term, it is also possible that sulodexide exerts 
anti-atheromasic effects. In experimental models, sulodexide 
protects endothelium from external injuries as demonstrated 
by a reduced number of desquamated endothelial cells.38 
Sulodexide could then stop the earliest phase of athero-
sclerosis, at the level of endothelial dysfunction, improving 
endothelium-dependent relaxation in small arteries.39 In a 
more advanced atherosclerosis phase, sulodexide inhibits 
neointimal proliferation after vascular injury of the carotid 
artery, as shown in an experimental model of restenosis after 
balloon angioplasty.40 Furthermore, in vitro heparin and 
heparinoids inhibit the proliferation of the vascular smooth 
muscle cells.41 This antiproliferative effect has also been 
supposed to be valid in humans, but only preliminary data 
are available.42
It has also been shown in humans that sulodexide 
  treatment could also improve some clinical parameters in 
patients with vascular dementia.43 Consequently it has also 
been used to prevent ischemic cerebral damage in patients 
with antphospholipid antibodies.44
Finally, different GAGs have been reported to be of 
benefit to the ischemic myocardium by preserving contractile 
  function and reducing tissue injury. In a rabbit model, 
  sulodexide also attenuated myocardial ischemia/reperfusion 
injury and the deposition of C-reactive protein in areas of 
infarction without affecting hemostasis.45
The prognostic value of most of these observations has 
yet to be demonstrated, but they appear to be interesting 
working hypotheses, especially in patients with either CKD 
and preclinical signs of cardiovascular diseases.
Conclusion
Preclinical and clinical evidence directly or indirectly support 
the hypothesis that new, adequately designed, long-term 
studies need to be carried out to investigate the potential role 
of sulodexide for proteinuric CKD management in diabetes 
patients, in particular to understand which kind of patients 
could obtain the most clinical advantage from this therapeutic 
approach. Presently, there is a clear lack of preventive and 
therapeutic tools for proteinuric syndromes, and each new 
active compound needs to be evaluated , in order to widen the 
therapeutic arsenal against CKD. Considering the previously 
reported large spectrum of its pharmacological properties, 
sulodexide seems to be able to play an important role in the 
treatment of these patients because of its actions not only at 
the renal level, but also on the whole vessel tree, which is 
usually severely affected in diabetes patients with CKD.
In conclusion, a relatively large body of literature 
  supports the antiproteinuric and nephroprotective effects of 
GAGs and sulodexide; however more basic clinical research 
is needed to understand which factors influence the drug’s 
efficacy and, consequently, which patients could therefore 
benefit most from this treatment.
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